ICU Medical, Inc. (NASDAQ:ICUI) Given Average Rating of “Buy” by Brokerages

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have been assigned a consensus rating of “Buy” from the six brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $168.00.

ICUI has been the topic of a number of research reports. KeyCorp lowered their target price on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. Piper Sandler lowered their target price on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Needham & Company LLC upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Wednesday, May 27th. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Finally, Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th.

Insider Buying and Selling

In related news, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the sale, the vice president directly owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This trade represents a 11.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David C. Greenberg sold 2,424 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the sale, the director directly owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This represents a 23.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

Several hedge funds have recently modified their holdings of ICUI. Hilton Head Capital Partners LLC acquired a new stake in shares of ICU Medical during the fourth quarter worth $32,000. Covestor Ltd lifted its holdings in shares of ICU Medical by 22.1% during the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 126 shares during the period. Strs Ohio lifted its holdings in shares of ICU Medical by 60.0% during the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 300 shares during the period. Rockefeller Capital Management L.P. lifted its holdings in shares of ICU Medical by 21.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 146 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of ICU Medical during the fourth quarter worth $120,000. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Stock Up 1.2%

ICUI stock opened at $136.61 on Tuesday. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60. ICU Medical has a twelve month low of $107.00 and a twelve month high of $160.29. The company’s 50 day moving average is $126.67 and its two-hundred day moving average is $138.60. The stock has a market cap of $3.41 billion, a P/E ratio of 73.84, a PEG ratio of 1.91 and a beta of 0.77.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.78 by $0.19. The business had revenue of $525.77 million for the quarter, compared to analyst estimates of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The company’s revenue for the quarter was down 12.3% compared to the same quarter last year. During the same period last year, the firm posted $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Research analysts expect that ICU Medical will post 6.5 earnings per share for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.